BPC-157 & TB-500 & GHK-Cu vs PT-141 (Bremelanotide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157 & TB-500 & GHK-Cu
The complete healing triad combining the Wolverine Stack with GHK-Cu (copper peptide) for comprehensive tissue repair. This blend addresses healing at multiple levels: cellular repair, collagen synthesis, and tissue regeneration.
Full details →PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 & TB-500 & GHK-Cu | PT-141 (Bremelanotide) |
|---|---|---|
| Mechanism | BPC-157 promotes angiogenesis and growth factor expression. TB-500 enhances cell migration and reduces inflammation. GHK-Cu activates genes involved in tissue remodeling, stimulates collagen and elastin production, and provides antioxidant protection. Together they support healing from multiple angles. | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. |
| Typical Dosage | Typical protocol: BPC-157 250-500mcg daily, TB-500 2-2.5mg twice weekly, GHK-Cu 1-2mg daily or applied topically for skin applications. | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. |
| Administration | BPC-157 and TB-500 via subcutaneous injection. GHK-Cu can be injected subcutaneously or used topically depending on the target area. Systemic and local administration may be combined. | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. |
| Side Effects | Generally well-tolerated. Possible injection site irritation, mild fatigue, or temporary skin discoloration with GHK-Cu. | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. |
| Best For |
What They Have in Common
Both BPC-157 & TB-500 & GHK-Cu and PT-141 (Bremelanotide) are commonly used for: